

Table 1. Demographic of all patients cumulatively diagnosed with BCRL by self-reported symptoms, arm circumference measurements, or clinician assessment.

	All (n=511)	BCRL (n=154)	No BCRL (n=346)	P value
Age, median (years)	56.0 ± 12.6	58.4 ± 12.5	54.9 ± 12.5	0.003
BMI	26.0 ± 7.7	27.7 ± 9.0	25.2 ± 6.8	0.002
Breast surgery				0.01
BCS	135 (27.9%)	28 (17.7%)	107 (30.3%)	
Mastectomy	349 (72.1%)	122 (77.2%)	227 (64.3%)	
Axillary surgery				0.09
SLNB/Axillary sampling	210 (45.4%)	60 (41.4%)	150 (47.2%)	
Axillary clearance	253 (54.6%)	85 (58.6%)	168 (52.8%)	
Reconstruction	48	11 (8.6%)	37 (14.5%)	0.10
Time interval from operation, months	88.8	80.1	92.6	0.09
Histology				0.19
DCIS	87 (17.0%)	23 (14.6%)	64 (18.1%)	
Ductal	318 (62.2%)	97 (61.4%)	221 (62.6%)	
Lobular	23 (4.5%)	5 (3.2%)	18 (5.1%)	
Others	83 (16.2%)	33 (20.9%)	50 (14.1%)	
Grade				0.047
1	72 (14.9%)	14 (9.3%)	58 (17.4%)	
2	226 (46.6%)	71 (47.0%)	155 (46.4%)	
3	187 (38.6%)	66 (43.7%)	121 (36.2%)	
Tumour stage				0.05
0	109 (21.3%)	32 (20.3%)	77 (21.8%)	
1	175 (34.3%)	42 (26.6%)	133 (37.7%)	
2	177 (34.6%)	65 (41.4%)	112 (31.7%)	
3	36 (7.1%)	12 (7.6%)	24 (6.8%)	
4	14 (2.7%)	7 (4.4%)	7 (2.0%)	
Nodal stage				0.01
0	366 (71.6%)	103 (65.2%)	263 (74.5%)	
1	93 (18.2%)	32 (20.3%)	61 (17.3%)	
2	31 (6.1%)	10 (6.3%)	21 (6.0%)	
3	21 (4.1%)	13 (8.2%)	8 (2.3%)	
No. of lymph node positive, mean	1.4 ± 4.0	2.5 ± 6.1	0.9 ± 2.5	0.0001
No. of lymph node excised, mean	11.7 ± 8.5	13.1 ± 9.2	11.1 ± 8.1	0.02
NPI				0.02
Good	151 (34.6%)	38 (28.4%)	113 (37.3%)	
Moderate	214 (49.0%)	65 (48.5%)	149 (49.2%)	
Poor	72 (16.5%)	31 (23.1%)	41 (13.5%)	
Receptor profile				0.18
ER+	382 (78.3%)	111 (74.5%)	271 (80.0%)	
TNBC	39 (7.6%)	16 (10.1%)	23 (6.5%)	0.15
Her2+	117 (26.5%)	33 (24.4%)	84 (27.5%)	0.51
Adjuvant chemotherapy	256 (50.1%)	91 (57.6%)	165 (46.7%)	0.02
Adjuvant endocrine therapy	352 (68.9%)	107 (67.7%)	245 (69.4%)	0.70
Adjuvant radiotherapy	247 (48.3%)	76 (48.1%)	171 (48.4%)	0.94

BCS: breast-conserving surgery; BMI: body mass index (kg/m²); DCIS: ductal carcinoma-in-situ; ER: estrogen receptor positive; Her2+: human epidermal growth factor receptor 2 positive; NPI: Nottingham Prognostic Index; SLNB: sentinel lymph node biopsy; TNBC: triple negative breast cancer